Filing Flows › Companies › Iradimed › Timeline
Iradimed stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+3.4% to $86.31
Iradimed (IRMD) stock rose 3% over the last 252 sessions, to $86.31. On the way it reported 4 quarters, its insiders filed 21 open-market trades and 1 Form 144 notice of planned sales, and the company filed 0 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 30, 2026 | Earnings | Earnings: missed the EPS estimate by 0.0% | −11.2% (−9.4% vs SPY) | −0.2% (+4.6% vs SPY) | — |
| Sep 3, 2026 | Form 144 | Form 144: Monty K. Allen plans to sell $123K | +0.5% (−0.6% vs SPY) | −5.1% (−4.1% vs SPY) | −0.9% (−1.7% vs SPY) |
| Sep 3, 2026 | Insider sale | Allen Monty K sold $123K | +0.5% (−0.6% vs SPY) | −5.1% (−4.1% vs SPY) | −0.9% (−1.7% vs SPY) |
| Jul 31, 2026 | Earnings | Earnings: beat the EPS estimate by 4.5% | −4.7% (−5.4% vs SPY) | −4.3% (−7.9% vs SPY) | −8.7% (−12.4% vs SPY) |
| Jun 4, 2026 | Insider sale | Scharen-Guivel Hilda Frederique sold $285K | +2.6% (+2.3% vs SPY) | +5.2% (+9.1% vs SPY) | +11.6% (+11.7% vs SPY) |
| May 1, 2026 | Earnings | Earnings: beat the EPS estimate by 10.1% | +4.3% (+4.1% vs SPY) | +3.9% (+2.1% vs SPY) | +10.0% (+4.7% vs SPY) |
| Mar 24, 2026 | Insider sale | Susi Roger E. sold $251K | +1.8% (+2.1% vs SPY) | −4.4% (−0.8% vs SPY) | −9.6% (−17.8% vs SPY) |
| Mar 23, 2026 | Insider sale | Susi Roger E. sold $502K | −0.3% (−1.3% vs SPY) | −2.2% (+0.1% vs SPY) | −11.0% (−19.2% vs SPY) |
| Mar 17, 2026 | Insider sale | Susi Roger E. sold $256K | +1.1% (+0.8% vs SPY) | −2.5% (−0.7% vs SPY) | −8.9% (−13.7% vs SPY) |
| Mar 16, 2026 | Insider sale | Susi Roger E. sold $507K | +2.0% (+1.0% vs SPY) | −0.2% (+1.6% vs SPY) | −6.3% (−11.3% vs SPY) |
| Mar 10, 2026 | Insider sale | Susi Roger E. sold $250K | −1.2% (−1.1% vs SPY) | +1.5% (+2.9% vs SPY) | −2.9% (−2.8% vs SPY) |
| Mar 9, 2026 | Insider sale | Susi Roger E. sold $500K | +1.5% (+0.6% vs SPY) | +1.0% (+2.5% vs SPY) | −5.4% (−3.7% vs SPY) |
| Mar 6, 2026 | Insider sale | Susi Roger E. sold $738K | −1.4% (−0.1% vs SPY) | −0.7% (+1.5% vs SPY) | −4.5% (−1.4% vs SPY) |
| Feb 13, 2026 | Insider sale | Allen Monty K sold $100K | 0.0% (−0.1% vs SPY) | +3.7% (+2.5% vs SPY) | +2.0% (+3.9% vs SPY) |
| Feb 10, 2026 | Earnings | Earnings: beat the EPS estimate by 12.5% | +9.1% (+9.4% vs SPY) | +4.7% (+6.4% vs SPY) | +5.1% (+7.7% vs SPY) |
| Jan 26, 2026 | Insider sale | Susi Roger E. sold $503K | −0.8% (−1.3% vs SPY) | −3.0% (−3.4% vs SPY) | −1.6% (−1.3% vs SPY) |
| Jan 20, 2026 | Insider sale | Susi Roger E. sold $509K | +1.0% (+3.0% vs SPY) | −1.9% (−2.0% vs SPY) | −0.5% (+0.2% vs SPY) |
| Jan 12, 2026 | Insider sale | Susi Roger E. sold $487K | −1.1% (−1.2% vs SPY) | +3.0% (+3.4% vs SPY) | +6.1% (+6.3% vs SPY) |
| Jan 5, 2026 | Insider sale | Susi Roger E. sold $488K | +2.9% (+2.2% vs SPY) | +3.5% (+2.0% vs SPY) | +2.6% (+1.6% vs SPY) |
| Dec 29, 2025 | Insider sale | Susi Roger E. sold $488K | +0.3% (+0.7% vs SPY) | +0.9% (+1.3% vs SPY) | +0.5% (−0.3% vs SPY) |
| Dec 22, 2025 | Insider sale | Susi Roger E. sold $484K | −0.1% (−0.7% vs SPY) | +0.6% (−0.5% vs SPY) | +6.7% (+5.4% vs SPY) |
| Dec 15, 2025 | Insider sale | Susi Roger E. sold $484K | +0.8% (+1.0% vs SPY) | +1.5% (+1.4% vs SPY) | +5.9% (+4.3% vs SPY) |
| Dec 11, 2025 | Insider sale | Glenn John sold $1.5M | +0.2% (0.0% vs SPY) | −2.8% (−0.4% vs SPY) | +1.2% (−0.1% vs SPY) |
| Dec 9, 2025 | Insider sale | Hawkins James B sold $290K | +1.3% (+1.4% vs SPY) | +1.6% (+2.0% vs SPY) | +5.2% (+4.0% vs SPY) |
| Nov 20, 2025 | Insider sale | Hawkins James B sold $265K | +1.1% (+2.6% vs SPY) | +7.0% (+4.4% vs SPY) | +12.1% (+9.1% vs SPY) |
| Nov 10, 2025 | Insider sale | Glenn John sold $900K | +2.0% (+0.5% vs SPY) | +0.2% (+0.1% vs SPY) | +13.9% (+12.2% vs SPY) |
Insiders’ record here
In the year on the chart, Iradimed's insiders reported 0 open-market buys ($0) and 21 sales ($9.9M). Of the 20 old enough to score, 13 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −9.6%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
Report card: every quarter against the estimate → Iradimed: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.